Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.08 HKD
−419.30 M HKD
426.53 K HKD
151.50 M
About IMMUNEONCO BIOPHARMACEUTICALS (SHAN
Sector
CEO
Wen Zhi Tian
Headquarters
Zhangjiang Science City
Website
Founded
2015
ISIN
CNE100006624
FIGI
BBG01J20MWK7
ImmuneOnco Biopharmaceuticals (Shanghai), Inc. operates as an early-stage biopharmaceutical company which develops and commercializes novel cancer immunotherapeutic products. It focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. The company was founded by Dr. Tian Wenzhi in June 2015 and is headquartered in Zhangjiang Science City, China.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 1541 is 4.70 HKD — it has decreased by −5.27% in the past 24 hours. Watch IMMUNEONCO BIOPHARMACEUTICALS (SHAN stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange IMMUNEONCO BIOPHARMACEUTICALS (SHAN stocks are traded under the ticker 1541.
1541 stock has fallen by −9.18% compared to the previous week, the month change is a −33.56% fall, over the last year IMMUNEONCO BIOPHARMACEUTICALS (SHAN has showed a −84.33% decrease.
1541 reached its all-time high on Oct 3, 2023 with the price of 32.15 HKD, and its all-time low was 3.21 HKD and was reached on Sep 11, 2024. View more price dynamics on 1541 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1541 stock is 8.99% volatile and has beta coefficient of 1.05. Track IMMUNEONCO BIOPHARMACEUTICALS (SHAN stock price on the chart and check out the list of the most volatile stocks — is IMMUNEONCO BIOPHARMACEUTICALS (SHAN there?
Today IMMUNEONCO BIOPHARMACEUTICALS (SHAN has the market capitalization of 1.98 B, it has decreased by −6.23% over the last week.
Yes, you can track IMMUNEONCO BIOPHARMACEUTICALS (SHAN financials in yearly and quarterly reports right on TradingView.
IMMUNEONCO BIOPHARMACEUTICALS (SHAN is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
1541 net income for the last half-year is −179.62 M HKD, while the previous report showed −225.39 M HKD of net income which accounts for 20.31% change. Track more IMMUNEONCO BIOPHARMACEUTICALS (SHAN financial stats to get the full picture.
No, 1541 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 145.00 employees. See our rating of the largest employees — is IMMUNEONCO BIOPHARMACEUTICALS (SHAN on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IMMUNEONCO BIOPHARMACEUTICALS (SHAN EBITDA is −356.57 M HKD, and current EBITDA margin is −90.52 K%. See more stats in IMMUNEONCO BIOPHARMACEUTICALS (SHAN financial statements.
Like other stocks, 1541 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUNEONCO BIOPHARMACEUTICALS (SHAN stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMUNEONCO BIOPHARMACEUTICALS (SHAN technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMUNEONCO BIOPHARMACEUTICALS (SHAN stock shows the neutral signal. See more of IMMUNEONCO BIOPHARMACEUTICALS (SHAN technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.